Investment Banking

Investment Banking 2018-05-11T20:39:19+00:00

Seeing all sides, and knowing what matters.

Sectors of Focus

7 b - Investment Banking
M&A TRANSACTIONS
25 m - Investment Banking
TRANSACTION SIZE
continents - Investment Banking
CONTINENTS

Seeing all sides, and knowing what matters.

Sectors of Focus

icon pharma - Investment Banking
PHARMACEUTICALS
icon services - Investment Banking
PHARMACEUTICAL SERVICES
icon health - Investment Banking
CONSUMER HEALTH & OTC

Typical Transaction

  • Sell-side M&A
  • Capital raising

EXPERIENCE + UNDERSTANDING

The Bourne Partners investment banking team understands opportunities from every angle and we concentrate on what’s important to you.

block-avista

Avista Pharma Solutions is a contract development, manufacturing, and testing organization.

SECTOR: Pharma Services/CDMO
YEAR: November 2018
DEAL SIZE: $252 million
MANDATE TYPE: Company Sell-side

block-endo2

Endo is a specialty pharmaceutical company that sells and manufactures branded and generic pharmaceuticals.

SECTOR: Pharma/OTC
YEAR: June 2018
DEAL SIZE: Undisclosed
MANDATE TYPE: Asset Divestiture

block-endo

Endo is a specialty pharmaceutical company that sells and manufactures branded and generic pharmaceuticals.

SECTOR: Pharma/OTC
YEAR: May 2018
DEAL SIZE: Undisclosed
MANDATE TYPE: Asset Divestiture

block-accelovance

Accelovance is a full service clinical Contract Research Organization focused on vaccine, oncology, and general medicine Phase I-IV programs.

SECTOR: Pharma Services
YEAR: April 2018
DEAL SIZE: $32 million
MANDATE TYPE: Company Sell-side

block-optimal

Optimal Research is a Site Management Organization (SMO) providing clinical site solutions to pharmaceutical and biotech companies, medical device companies, and CROs.

SECTOR: Pharma Services
YEAR: September 2017
DEAL SIZE: Undisclosed
MANDATE TYPE: Company Sell-side

block-carlyle

Albany Molecular Research is a contract research and manufacturing company providing integrated drug discovery, development, and manufacturing services primarily in the U.S., Europe and Asia.

SECTOR: Pharma Services
YEAR: April 2017
DEAL SIZE: $1.63 billion
MANDATE TYPE: Company Buy-side

block-prophase

Prophase manufactures, markets, and distributes a range of homeopathic and health care products to general public in the United States.

SECTOR: OTC
YEAR: March 2017
DEAL SIZE: $50 million
MANDATE TYPE: Product Sell-side

block-cinven

AMCo is a niche specialty pharmaceutical company, marketing its vast portfolio of niche medicines to patients in more than 100 countries.

SECTOR: Pharma
YEAR: October 2015
DEAL SIZE: $3.5 billion
MANDATE TYPE: Company Sell-side

CONNECTION + COLLABORATION

We collaborate with industry stakeholders and draw on strong relationships on both the advisory and strategic capital sides.

And we don’t stop until the deal is done.